Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K. Hata N, et al. Among authors: mizoguchi m. J Neurooncol. 2020 Feb;146(3):451-458. doi: 10.1007/s11060-019-03339-0. Epub 2020 Feb 4. J Neurooncol. 2020. PMID: 32020475
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M. Takigawa K, et al. Among authors: mizoguchi m. J Neurooncol. 2021 Sep;154(2):187-196. doi: 10.1007/s11060-021-03812-9. Epub 2021 Jul 28. J Neurooncol. 2021. PMID: 34322829 Free PMC article.
Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study.
Funakoshi Y, Takigawa K, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Otsuji R, Sako A, Yoshitake T, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Yoshimoto K. Funakoshi Y, et al. Among authors: mizoguchi m. World Neurosurg. 2022 Mar;159:e479-e487. doi: 10.1016/j.wneu.2021.12.075. Epub 2021 Dec 25. World Neurosurg. 2022. PMID: 34958993
Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor).
Yoshimoto K, Kada A, Kuga D, Hatae R, Murata H, Akagi Y, Nishimura K, Kurogi R, Nishimura A, Hata N, Mizoguchi M, Sayama T, Iihara K. Yoshimoto K, et al. Among authors: mizoguchi m. Neurol Med Chir (Tokyo). 2016 Nov 15;56(11):664-673. doi: 10.2176/nmc.oa.2016-0172. Epub 2016 Sep 27. Neurol Med Chir (Tokyo). 2016. PMID: 27680329 Free PMC article.
Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status.
Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Shono T, Mizoguchi M, Iihara K. Hata N, et al. Among authors: mizoguchi m. Onco Targets Ther. 2017 Jan 18;10:429-437. doi: 10.2147/OTT.S125587. eCollection 2017. Onco Targets Ther. 2017. PMID: 28176936 Free PMC article.
Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y, Miura F, Araki H, Mizoguchi M, Hata N, Kuga D, Hatae R, Akagi Y, Amemiya T, Fujioka Y, Arai Y, Yoshida A, Shibata T, Yoshimoto K, Iihara K, Ito T. Sangatsuda Y, et al. Among authors: mizoguchi m. Sci Rep. 2020 Sep 30;10(1):16162. doi: 10.1038/s41598-020-73116-x. Sci Rep. 2020. PMID: 32999376 Free PMC article.
494 results